|
(MoneyNewsWire.Net, April 27, 2018 ) The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9%. The growth of Overactive Bladder Treatment market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity, aggressive marketing strategies by pharma companies, and the development of new therapies to treat bladder overactivity. However, the undesired systemic effects caused by anticholinergics may hinder the growth of the Overactive Bladder Treatment market to a certain extent.
Explore More Information about report @ https://www.researchcosmos.com/reports/global-overactive-bladder-treatment-market-analysis-and-forecast-to-2022-growth-opportunity-assess/9906517
Therapy approvals are regulated by various regional regulatory authorities. The changing regulatory scenario favoring overactive bladder treatments in a number of countries, such as the U.K. and Japan, will offer significant growth opportunities for Overactive Bladder Treatment market players. For example, the U.K.’s National Institutes for Health and Care Excellence (NICE) reimburses the BOTOX therapy. In 2007, the Japanese Ministry of Health, Labour and Welfare (MHLW) launched an action plan to promote the safe use of generics.
The report analyzes the Overactive Bladder Treatment market by pharmacotherapy, disease type, and region. On the basis of pharmacotherapy, the anticholinergics segment accounted for the largest share in 2016, being the first line of medical treatment on bladder overactivity. Based on disease type, the idiopathic overactive bladder treatment segment accounted for the largest share in 2016. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.
Request free sample @ https://www.researchcosmos.com/request/9906517
Geographically, the global Overactive Bladder Treatment market is segmented into the U.S., Europe, Asia-Pacific, and the Rest of the World. In 2016, the U.S. dominated the Overactive Bladder Treatment market and this is primarily attributed to its well-established healthcare industry with favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. The Rest of Asia-Pacific region is expected to witness the highest CAGR during the forecast period owing to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on overactive bladder.
In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the global Overactive Bladder Treatment market. Some of the other players competing in Overactive Bladder Treatment market are Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International Plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).
Check for discount @ https://www.researchcosmos.com/discount/9906517
About Us:
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
Research Cosmos
Dani Rodriguez
+1 888 709 8757
dani@researchcosmos.com
Source: EmailWire.Com 
|
